SeaBridge Investment Advisors LLC Takes Position in iShares Biotechnology ETF (NASDAQ:IBB)

SeaBridge Investment Advisors LLC acquired a new position in shares of iShares Biotechnology ETF (NASDAQ:IBB) in the 4th quarter, according to its most recent 13F filing with the SEC. The fund acquired 6,093 shares of the financial services provider’s stock, valued at approximately $806,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Darwin Wealth Management LLC acquired a new stake in iShares Biotechnology ETF in the 3rd quarter worth about $29,000. Highline Wealth Partners LLC acquired a new position in iShares Biotechnology ETF during the third quarter worth approximately $30,000. Ashton Thomas Securities LLC purchased a new position in iShares Biotechnology ETF during the third quarter worth approximately $36,000. Modus Advisors LLC acquired a new position in shares of iShares Biotechnology ETF in the 4th quarter valued at $41,000. Finally, Crews Bank & Trust acquired a new stake in shares of iShares Biotechnology ETF during the 4th quarter worth $44,000. Hedge funds and other institutional investors own 62.45% of the company’s stock.

iShares Biotechnology ETF Trading Down 0.2 %

Shares of NASDAQ IBB opened at $138.66 on Friday. The stock has a fifty day moving average price of $136.37 and a 200 day moving average price of $141.63. iShares Biotechnology ETF has a 12-month low of $123.60 and a 12-month high of $150.57.

iShares Biotechnology ETF Cuts Dividend

The firm also recently announced a dividend, which was paid on Friday, December 20th. Stockholders of record on Tuesday, December 17th were paid a dividend of $0.0624 per share. The ex-dividend date of this dividend was Tuesday, December 17th.

About iShares Biotechnology ETF

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.